March 20th 2023
Combination treatment with nivolumab and relatlimab appears to be a safe treatment option for patients with advanced melanoma who have progressed on prior anti–PD-L1 therapy.
February 28th 2023
February 28th 2023
February 23rd 2023
COUNTERPOINT: Surgical Management of Lymph Node Basin in Sentinel Lymph Node–Positive MelanomaOctober 15th 2016
Ironically, the patients who can benefit the most from CLND in terms of regional nodal basin disease control are the patients who are least likely to experience a survival benefit.
Impediments to Skin Cancer Prevention Among Minorities, UninsuredSeptember 16th 2016
Lack of knowledge and a belief that dark skin protects against skin cancer are among the barriers preventing minority, uninsured, and immigrant populations from adopting methods for skin cancer prevention.
The Role of Intralesional Therapies in MelanomaMay 15th 2016
Through the emergence of new immunotherapies, treatment of melanoma is undergoing a long-awaited revolution. Ongoing research will clarify the outlines of the place that intralesional therapies will occupy in the therapeutic armamentarium in the years ahead.
A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination ApproachMay 15th 2016
Perhaps the greatest attraction and chief benefit of intratumoral therapies is their ability to synergize with systemic checkpoint therapies and accelerate the development of a lymphoid infiltrate and perhaps secondary lymphoid structures in vivo, which in turn can result in systemic mobilization of a T-cell response: the local injection–global effect model.
Complete Dissection After Positive Melanoma SLN Biopsy Necessary?May 11th 2016
A recent trial found no survival difference in patients with melanoma with a positive sentinel lymph node biopsy who underwent complete lymph node dissection compared with those who did not undergo dissection. However, the trial failed to achieve the required number of events and is, therefore, underpowered.